Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T16:11:35.601Z.
Calculation as of: 2026-10-06T16:11:35.601Z.
Quote observation: 2026-10-06T16:09:28.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 77dbea8aa1c4b6afac8bad226ab17e7d6a7ad6f552ac01c17f7c344859946cda
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$114.79M
EV/FCF Ratio
N/A
TTM Avg
1.44x
3Y Avg
1.44x
5Y Avg
1.44x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | $117.53M | N/A | N/A | N/A | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $117.29M | N/A | N/A | N/A | N/A |
| Genelux Corporation (GNLX)vs › | $116.14M | N/A | N/A | N/A | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.68M | N/A | N/A | N/A | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $114.79M | N/A | 1.44x | 1.44x | 1.44x |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.86M | N/A | N/A | N/A | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $122.27M | N/A | N/A | N/A | N/A |
| MaxCyte, Inc. (MXCT)vs › | $113.01M | N/A | N/A | N/A | N/A |
| enGene Holdings Inc. (ENGN)vs › | $122.30M | N/A | N/A | N/A | N/A |
| Cibus, Inc. (CBUS)vs › | $122.89M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
